NBIX

NEUROCRINE BIOSCIENCES INC

8 filings tracked

healthcarebiotechnologyLARGE ($10B-200B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

neutralMay 28

Re-election of Class III directors ensures board continuity.

management change

30%

bearishMay 28

Approval of Amended 2025 Equity Plan increases potential for share dilution.

dilution risk

60%

bullishMay 5

Net income surged to $197.9 million from $7.9 million YoY.

earnings beat

90%

neutralMay 5

Acquiring Soleno Therapeutics for $2.9 billion in cash.

acquisition

80%

bullishMay 5

Operating margins increased to 23.7% due to scalable commercial growth.

margin expansion

70%

bullishMay 5

Active share repurchase program with $276.3 million remaining.

buyback

50%

bullishMay 5

Net income surged to $197.9 million from $7.9 million YoY.

earnings beat

90%

neutralMay 5

Acquiring Soleno Therapeutics for $2.9 billion in cash.

acquisition

80%

bullishMay 5

Operating margins increased to 23.7% due to scalable commercial growth.

margin expansion

70%

bullishMay 5

Active share repurchase program with $276.3 million remaining.

buyback

50%

bullishMay 5

Net income surged to $197.9 million from $7.9 million YoY.

earnings beat

90%

neutralMay 5

Acquiring Soleno Therapeutics for $2.9 billion in cash.

acquisition

80%

bullishMay 5

Operating margins increased to 23.7% due to scalable commercial growth.

margin expansion

70%

bullishMay 5

Active share repurchase program with $276.3 million remaining.

buyback

50%

bullishMay 5

Net income surged to $197.9 million from $7.9 million YoY.

earnings beat

90%

neutralMay 5

Acquiring Soleno Therapeutics for $2.9 billion in cash.

acquisition

80%

bullishMay 5

Operating margins increased to 23.7% due to scalable commercial growth.

margin expansion

70%

bullishMay 5

Active share repurchase program with $276.3 million remaining.

buyback

50%

bullishMay 5

Net income surged to $197.9 million from $7.9 million YoY.

earnings beat

90%

neutralMay 5

Acquiring Soleno Therapeutics for $2.9 billion in cash.

acquisition

80%

bullishMay 5

Operating margins increased to 23.7% due to scalable commercial growth.

margin expansion

70%

bullishMay 5

Active share repurchase program with $276.3 million remaining.

buyback

50%

bullishMay 5

Net income surged to $197.9 million from $7.9 million YoY.

earnings beat

90%

neutralMay 5

Acquiring Soleno Therapeutics for $2.9 billion in cash.

acquisition

80%

bullishMay 5

Operating margins increased to 23.7% due to scalable commercial growth.

margin expansion

70%

bullishMay 5

Active share repurchase program with $276.3 million remaining.

buyback

50%

bullishMay 5

Net income surged to $197.9 million from $7.9 million YoY.

earnings beat

90%

neutralMay 5

Acquiring Soleno Therapeutics for $2.9 billion in cash.

acquisition

80%

bullishMay 5

Operating margins increased to 23.7% due to scalable commercial growth.

margin expansion

70%

bullishMay 5

Active share repurchase program with $276.3 million remaining.

buyback

50%

Filing History

8-KMay 28, 2026

The 8-K filing confirms that Neurocrine Biosciences has successfully navigated its annual governance requirements, ratifying its board of directors and its accounting firm while passing a critical update to its equity incentive structure. While the bulk of the vote was positive, the presence of a distinct minority opposition highlights the ongoing tension between management's need for flexible incentive tools and shareholders' concerns over dilution. The overall impact is a stabilized leadership mandate, though investors will likely monitor the actual issuance of shares under the new plan to gauge the true cost of this alignment.

10-QMay 5, 2026

The first quarter of 2026 marks a pivotal transition for Neurocrine Biosciences, characterized by a shift toward large-scale commercialization and aggressive M&A. The filing reveals a company that is winning the battle for market share in its core indications but is simultaneously betting its balance sheet on the Soleno acquisition. The surge in net income to $197.9 million proves the business model's viability, yet the accompanying cash outflows highlight the tension between returning capital to shareholders and funding strategic growth. Ultimately, the investment thesis now hinges on whether the revenue acceleration from CRENESSITY and the integration of Soleno can outpace the combined headwinds of generic entry and federal drug pricing mandates. Investors are left weighing a high-growth, high-margin commercial trajectory against a backdrop of significant liquidity risk and concentrated revenue streams.